Author Archives: admin


Global Stem Cell Banking research report by, players, types and applications, forecast to 2029 – Owned

A latest specialized intelligence report published by KandJ Market Research with the title 2020-2029 Report on Global Stem Cell Banking Market by Player, Region, Type, Application and Sales Channel has the ability to help the decision-makers in the most important market in the world that has played a significantly important role in making a progressive impact on the global economy. The Global Stem Cell Banking Market Report presents and showcases a vital vision of the global scenario in terms of market size, market potentials, and competitive environment. The study is derivative from primary and secondary statistical data and consists of qualitative and quantitative analysis of the industry and key players.

The latest report includes Impact of Coronavirus(Covid-19) on the Stem Cell Banking Industry, it includes on Industry Upstream, Industry Downstream, Industry Channels, Industry Competition, and finally on Industry Employment.

The Final Report Will Comprise the Impact of COVID 19 Analyses in This Stem Cell Banking Industry. For Sample Report & Graphs & Charts @: https://www.kandjmarketresearch.com/sample-request/360383

The global Stem Cell Banking market is showing promising signs that can be explored well in the coming days to achieve a notable valuation by the end of 2029. The report is expected to consider the time-frame as the forecast period and it would deal with the market accordingly. Growth-inducing factors have been monitored closely in the report to gauge well the progress of the market. Each factor can play a significant role and has been given proper space on the basis of which the market can devise strategies. It has tracked various associated fields as well to get a proper map of how these end user industries are impacting the market and can take the market forward. The report has credibility as it banks on the expertise of adept researchers who fetch numbers from a pool of information and sieve them as per the requirement. In the process, they have gone through the market by having it analysed on top-down and bottom-up basis.

Key Segments Studied in the Global Stem Cell Banking Market:-

Leading players of Stem Cell Banking including:

Market split by Type, can be divided into:

Market split by Application, can be divided into:

Ask for Discount @https://www.kandjmarketresearch.com/discount/360383

Market split by Sales Channel, can be divided into:-

Market Analysis by Regions

The segmentation plays a prominent role in dealing with the growth of the Stem Cell Banking market where various types and applications are promoting better understanding of the market. This segmentation has a strong foundation in volume-wise and value-wise data which backs the process of understanding the market scenario with numbers. The market has been combed through properly to get all the factors in line. The report has been enriched interviews as a first hand method of getting data. These interviews include chats with top market players, market analysts, distributors, people in the field of research and development and others owing to which the reliability of the report has increased significantly.

Regional market analysis of the report has backed the study of different regions as an attempt to understand growth pockets that can be beneficial for the market. The regional analysis has import, export, and other processes covered. Players who are getting involved in the market for a better growth are looking for these growth pockets to capitalize on the opportunities provided and find new scopes for growth. Certain countries have been tracked in detail to monitor them closely as they can be major markets in the coming years. Benefits like better infrastructure, cost-effective labor, access to raw materials, they offer have become luring factors for many market players and they want to expand their business to these regions to increase their profit margin.

Read More Detailed Information regarding Stem Cell Banking Industry with Covid-19 Updates @ https://www.kandjmarketresearch.com/reports/360383-2020-2029-report-on-global-stem-cell-banking-market-by-player-region-type-application-and-sales-channel

About Us:

Kandjmarketresearch.com is part of the KnowledgeNJournals Research Firm which provides premium progressive market research reports, statistical surveying, analysis & forecast data for industries and governments from hundreds of publishers around the world.

We have almost all top publishers reports in our collection to provide you with instant online access to the worlds most complete and fresh database on a Daily Basis. We are at KandJ Market Research are inspired to help our clients grow by providing appropriate business insight with our huge market intelligence source.

If you have any special requirements for the report, please let us know and we will offer you a customized report on separate regional or country-level reports.

Contact us:

KandJ Market Research

(Part of KnowledgeNJournals Research)

E-mail: [emailprotected]

Website: https://www.kandjmarketresearch.com

Call us: +1 661 636 6162 | +91 932 580 2062

Follow this link:
Global Stem Cell Banking research report by, players, types and applications, forecast to 2029 - Owned

Cell Separation Technology Market to Surpass ~ US$ 13.6 Billion by 2027 – Cole of Duty

Transparency Market Research (TMR) has published a new report on the global cell separation technology market for the forecast period of 20192027. According to the report, the global cell separation technology market was valued at ~ US$ 5 Bn in 2018, and is projected to expand at a double-digit CAGR during the forecast period.

Overview

Cell separation, also known as cell sorting or cell isolation, is the process of removing cells from biological samples such as tissue or whole blood. Cell separation is a powerful technology that assists biological research. Rising incidences of chronic illnesses across the globe are likely to boost the development of regenerative medicines or tissue engineering, which further boosts the adoption of cell separation technologies by researchers.

Expansion of the global cell separation technology market is attributed to an increase in technological advancements and surge in investments in research & development, such as stem cell research and cancer research. The rising geriatric population is another factor boosting the need for cell separation technologies Moreover, the geriatric population, globally, is more prone to long-term neurological and other chronic illnesses, which, in turn, is driving research to develop treatment for chronic illnesses. Furthermore, increase in the awareness about innovative technologies, such as microfluidics, fluorescent-activated cells sorting, and magnetic activated cells sorting is expected to propel the global cell separation technology market.

Request Brochure of Report https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1925

North America dominated the global cell separation technology market in 2018, and the trend is anticipated to continue during the forecast period. This is attributed to technological advancements in offering cell separation solutions, presence of key players, and increased initiatives by governments for advancing the cell separation process. However, insufficient funding for the development of cell separation technologies is likely to hamper the global cell separation technology market during the forecast period. Asia Pacific is expected to be a highly lucrative market for cell separation technology during the forecast period, owing to improving healthcare infrastructure along with rising investments in research & development in the region.

Rising Incidences of Chronic Diseases, Worldwide, Boosting the Demand for Cell Therapy

Incidences of chronic diseases such as diabetes, obesity, arthritis, cardiac diseases, and cancer are increasing due to sedentary lifestyles, aging population, and increased alcohol consumption and cigarette smoking. According to the World Health Organization (WHO), by 2020, the mortality rate from chronic diseases is expected to reach 73%, and in developing counties, 70% deaths are estimated to be caused by chronic diseases. Southeast Asia, Eastern Mediterranean, and Africa are expected to be greatly affected by chronic diseases. Thus, the increasing burden of chronic diseases around the world is fuelling the demand for cellular therapies to treat chronic diseases. This, in turn, is driving focus and investments on research to develop effective treatments. Thus, increase in cellular research activities is boosting the global cell separation technology market.

Increase in Geriatric Population Boosting the Demand for Surgeries

The geriatric population is likely to suffer from chronic diseases such as cancer and neurological disorders more than the younger population. Moreover, the geriatric population is increasing at a rapid pace as compared to that of the younger population. Increase in the geriatric population aged above 65 years is projected to drive the incidences of Alzheimers, dementia, cancer, and immune diseases, which, in turn, is anticipated to boost the need for corrective treatment of these disorders. This is estimated to further drive the demand for clinical trials and research that require cell separation products. These factors are likely to boost the global cell separation technology market.

According to the United Nations, the geriatric population aged above 60 is expected to double by 2050 and triple by 2100, an increase from 962 million in 2017 to 2.1 billion in 2050 and 3.1 billion by 2100.

Request for Analysis of COVID19 Impact on Cell Separation Technology Market https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=1925

Productive Partnerships in Microfluidics Likely to Boost the Cell Separation Technology Market

Technological advancements are prompting companies to innovate in microfluidics cell separation technology. Strategic partnerships and collaborations is an ongoing trend, which is boosting the innovation and development of microfluidics-based products. Governments and stakeholders look upon the potential in single cell separation technology and its analysis, which drives them to invest in the development of microfluidics. Companies are striving to build a platform by utilizing their expertise and experience to further offer enhanced solutions to end users.

Stem Cell Research to Account for a Prominent Share

Stem cell is a prominent cell therapy utilized in the development of regenerative medicine, which is employed in the replacement of tissues or organs, rather than treating them. Thus, stem cell accounted for a prominent share of the global market. The geriatric population is likely to increase at a rapid pace as compared to the adult population, by 2030, which is likely to attract the use of stem cell therapy for treatment. Stem cells require considerably higher number of clinical trials, which is likely to drive the demand for cell separation technology, globally. Rising stem cell research is likely to attract government and private funding, which, in turn, is estimated to offer significant opportunity for stem cell therapies.

Biotechnology & Pharmaceuticals Companies to Dominate the Market

The number of biotechnology companies operating across the globe is rising, especially in developing countries. Pharmaceutical companies are likely to use cells separation techniques to develop drugs and continue contributing through innovation. Growing research in stem cell has prompted companies to own large separate units to boost the same. Thus, advancements in developing drugs and treatments, such as CAR-T through cell separation technologies, are likely to drive the segment.

As per research, 449 public biotech companies operate in the U.S., which is expected to boost the biotechnology & pharmaceutical companies segment. In developing countries such as China, China Food and Drug Administration (CFDA) reforms pave the way for innovation to further boost biotechnology & pharmaceutical companies in the country.

Buy Cell Separation Technology Market Report at https://www.transparencymarketresearch.com/checkout.php?rep_id=1925&ltype=S

Global Cell Separation Technology Market: Prominent Regions

North America to Dominate Global Market, While Asia Pacific to Offer Significant Opportunity

In terms of region, the global cell separation technology market has been segmented into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the global market in 2018, followed by Europe. North America accounted for a major share of the global cell separation technology market in 2018, owing to the development of cell separation advanced technologies, well-defined regulatory framework, and initiatives by governments in the region to further encourage the research industry. The U.S. is a major investor in stem cell research, which accelerates the development of regenerative medicines for the treatment of various long-term illnesses.

The cell separation technology market in Asia Pacific is projected to expand at a high CAGR from 2019 to 2027. This can be attributed to an increase in healthcare expenditure and large patient population, especially in countries such as India and China. Rising medical tourism in the region and technological advancements are likely to drive the cell separation technology market in the region.

Launching Innovative Products, and Acquisitions & Collaborations by Key Players Driving Global Cell Separation Technology Market

The global cell separation technology market is highly competitive in terms of number of players. Key players operating in the global cell separation technology market include Akadeum Life Sciences, STEMCELL Technologies, Inc., BD, Bio-Rad Laboratories, Inc., Miltenyi Biotech, 10X Genomics, Thermo Fisher Scientific, Inc., Zeiss, GE Healthcare Life Sciences, PerkinElmer, Inc., and QIAGEN.

These players have adopted various strategies such as expanding their product portfolios by launching new cell separation kits and devices, and participation in acquisitions, establishing strong distribution networks. Companies are expanding their geographic presence in order sustain in the global cell separation technology market. For instance, in May 2019, Akadeum Life Sciences launched seven new microbubble-based products at a conference. In July 2017, BD received the U.S. FDAs clearance for its BD FACS Lyric flow cytometer system, which is used in the diagnosis of immunological disorders.

More Trending Reports by Transparency Market Research

Automated External Defibrillators Market: https://www.biospace.com/article/automated-external-defibrillators-market-semi-automatic-segment-to-lead-global-market-as-disposable-income-rises/

Read our Case study at https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

About Us

Transparency Market Research is a global market intelligence company providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for several decision makers. Our experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Our data repository is continuously updated and revised by a team of research experts so that it always reflects latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

Contact

Transparency Market Research,

90 Sate Street, Suite 700,

Albany, NY 12207

Tel: +1-518-618-1030

USA Canada Toll Free: 866-552-3453

Website: https://www.transparencymarketresearch.com/

See the original post here:
Cell Separation Technology Market to Surpass ~ US$ 13.6 Billion by 2027 - Cole of Duty

Expected Growth In Stem Cells Market from 2020-2026 to Guide : Trends, Analysis by Manufacturers, Regions, Type and Application – Owned

Detailed Analysis & SWOT analysis, Stem Cells Market Trends 2020, Stem Cells Market Growth 2020, Stem Cells Industry Share 2020, Stem Cells Industry Size, Stem Cells Market Research, Stem Cells Market Analysis, Stem Cells market Report speaks about the manufacturing process. The process is analyzed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labor cost, etc.) and the actual process of whole Enterprise Stem Cells Market.

Stem Cells market 2020 is a professional and in-intensity look at on the modern state of the key-word industry. The document provides a simple review of the key-word marketplace together with definitions, classifications, programs and chain shape. The key-word enterprise evaluation is supplied for the worldwide marketplace which include improvement records, competitive landscape evaluation, and principal local development popularity.

Ask for a Sample Report 2020

The Stem Cells marketplace file elaborates Stem Cells industry evaluation with various definitions and category, Product kinds & its packages and chain shape. Stem Cells market document presentations the manufacturing, sales, charge, and market proportion and boom rate of every type as following.

2020 Short Detail of this Stem Cells market report:

Stem cells are a class of undifferentiated cells that are able to differentiate into specialized cell types. Commonly, stem cells come from two main sources: Embryos formed during the blastocyst phase of embryological development (embryonic stem cells) and Adult tissue (adult stem cells).

Both types are generally characterized by their potency, or potential to differentiate into different cell types (such as skin, muscle, bone, etc.).

Market Analysis and Insights: Global Stem Cells Market

In 2019, the global Stem Cells market size was expected to grow by the end of 2026, with a steady rate of CAGR during 2021-2026.

Global Stem Cells Scope and Market Size

Stem Cells market is segmented by Type, and by Application. Players, stakeholders, and other participants in the global Stem Cells market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2015-2026.

Segment by Type, the Stem Cells market is segmented into Umbilical Cord Blood Stem Cell, Embryonic Stem Cell, Adult Stem Cell, Other, etc.

Segment by Application, the Stem Cells market is segmented into Diseases Therapy, Healthcare, etc.

Regional and Country-level Analysis

The Stem Cells market is analysed and market size information is provided by regions (countries).

The key regions covered in the Stem Cells market report are North America, Europe, China, Japan, Southeast Asia, India and Central & South America, etc.

The report includes country-wise and region-wise market size for the period 2015-2026. It also includes market size and forecast by Type, and by Application segment in terms of revenue for the period 2015-2026.

Competitive Landscape and Stem Cells Market Share Analysis

Stem Cells market competitive landscape provides details and data information by vendors. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by player for the period 2015-2020. Details included are company description, major business, company total revenue and the revenue generated in Stem Cells business, the date to enter into the Stem Cells market, Stem Cells product introduction, recent developments, etc.

The major vendors include CCBC, Vcanbio, Boyalife, Beikebiotech, etc.

This report focuses on the global Stem Cells status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Stem Cells development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

Get a sample copy of the report

Stem Cells Market by Product Type:

Stem Cells Market by Applications:

Get a Sample Copy of the Report https://www.360marketupdates.com/enquiry/request-sample/14848726

Next part of the Stem Cells Market analysis report speaks about the manufacturing process. The process is analysed thoroughly with respect three points, viz. raw material and equipment suppliers, various manufacturing associated costs (material cost, labour cost, etc.) and the actual process. Stem Cells market competition by top manufacturers, with production, price, and revenue (value) and market share for each manufacturer as per following;

Top Manufacturer Included in Stem Cells Market:

And More

Feel Free to Ask Question Before Purchasing the Report at https://www.360marketupdates.com/enquiry/pre-order-enquiry/14848726

After the basic information, the Stem Cells report sheds light on the production, production plants, their capacities, global production and revenue are studied. Also, the Stem Cells Market growth in various regions and R&D status are also covered.

Stem Cells Market Report by Key Region:

The global Stem Cells market is anticipated to rise at a considerable rate during the forecast period, between 2020 and 2026. In 2020, the market was growing at a mild rate and with the rising adoption of strategies by key players, the market is predicted to rise over the projected horizon. The report also tracks the most recent market dynamics, like driving factors, restraining factors, and industry news like mergers, acquisitions, and investments.

The report can help to know the market and strategize for business expansion accordingly. Within the strategy analysis, it gives insights from market positioning and marketing channel to potential growth strategies, providing in-depth analysis for brand fresh entrants or exists competitors within the Stem Cells industry. Global Stem Cells Market Report 2020 provides exclusive statistics, data, information, trends and competitive landscape details during this niche sector.

Have any query? Ask our expert @ http://www.360marketupdates.com/enquiry/pre-order-enquiry/444

Further in the report, Stem Cells Market is examined for price, cost and gross revenue. These three points are analysed for types, companies and regions. In prolongation with this data sale price for various types, applications and region is also included. The Stem Cells Industry consumption for major regions is given. Additionally, type wise and application wise consumption figures are also given.

To provide information on competitive landscape, this report includes detailed profiles of Stem Cells Market key players. For each player, product details, capacity, price, cost, gross and revenue numbers are given. Their contact information is provided for better understanding.

Other Major Topics Covered in Stem Cells market research report are as follows:

And another component .

Purchase this report (Price 3900 USD for a Single-User License) https://www.360marketupdates.com/purchase/14848726

Cold Chain Monitoring Market will Turn over CAGR of 7.7% to success Revenue to Cross USD 5863.5 million in 2020 to 2025 Top Companies report covers, Market-specific challenges, new opportunities planning, consumption by Regional data, Trends, and Forecasts

ICAD (Intracranial Atherosclerotic Disease) Pathology Market will Revenue to Cross USD 227.4 million in 2020 to 2025 Top Companies report covers, Market-specific challenges, New opportunities planning, and consumption by Regional data

Printer Toner Cartridge Market Size in 2020(New Report)- Top Manufacturers, Regions, Market Distribution, Supply Demand Scenario, Type & Application and Forecast to 2026

Asphalt Plants (Asphalt Mixing Plants) Market will Turn over CAGR of roughly 3.4% to success Revenue to Cross reach 2860 million USD in 2020 to 2024 TopCompanies report covers, consumption by Regional data

More here:
Expected Growth In Stem Cells Market from 2020-2026 to Guide : Trends, Analysis by Manufacturers, Regions, Type and Application - Owned

Hyperbaric Oxygen Therapy Boosts Cognitive Function in Older Adults, Says Study – Technology Networks

Read Time:

The Sagol Center for Hyperbaric Medicine and Research at Shamir Medical Center, together with the Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, have announced that a peer-reviewed study has demonstrated for the first time that hyperbaric oxygen therapy (HBOT) can significantly enhance the cognitive performance of healthy older adults. The main areas of improvement were attention, information processing speed, and executive function, in addition to the global cognitive function, all of which typically decline with age. Moreover, there was a significant correlation between the cognitive changes and improved cerebral blood flow in specific brain locations.

Professor Shai Efrati, Head of the Sagol Center for Hyperbaric Medicine and Research, and Head of Research & Development at Shamir Medical Center, and an Associate Professor at Sackler School of Medicine and Sagol School of Neuroscience at Tel Aviv University, and Dr. Amir Hadanny, the Sagol Center for Hyperbaric Medicine and Research, designed the study based on a unique HBOT protocol developed at the Sagol Center over the past 10 years. The randomized controlled clinical trial included 63 healthy adults (>64) who underwent either HBOT (n=33) or a control period (n=30) for three months. The study's primary endpoint included a change in general cognitive function measured by a standardized comprehensive battery of computerized cognitive assessments before and after the intervention or control. Cerebral blood flow (CBF) was evaluated by a novel magnetic resonance imaging technique for brain perfusion.

"Age-related cognitive and functional decline has become a significant concern in the Western world. Major research efforts around the world are focused on improving the cognitive performance of the so-called normal' aging population," said Prof. Efrati. "In our study, for the first time in humans, we have found an effective and safe medical intervention that can address this unwanted consequence of our age-related deterioration."

"Over years of research, we have developed an advanced understanding of HBOT's ability to restore brain function. In the past, we have demonstrated HBOT's potential to improve/treat brain injuries such as stroke, traumatic brain injury and anoxic brain injury (due to sustained lack of oxygen supply) by increasing brain blood flow and metabolism," explained Dr. Amir Hadanny. "This landmark research could have a far-reaching impact on the way we view the aging process and the ability to treat its symptoms."

During HBOT, the patient breaths in pure oxygen in a pressurized chamber where the air pressure is increased to twice that of normal air. This process increases oxygen solubility in the blood that travels throughout the body. The added oxygen stimulates the release of growth factors and stem cells, which promote healing. HBOT has been applied worldwide mostly to treat chronic non-healing wounds.

There is a growing body of evidence on the regenerative effects of HBOT. The researchers have demonstrated that the combined action of delivering high levels of oxygen (hyperoxia) and pressure (hyperbaric environment), leads to significant improvement in tissue oxygenation while targeting both oxygen and pressure sensitive genes, resulting in restored and enhanced tissue metabolism. Moreover, these targeted genes induce stem cell proliferation, reduce inflammation and induce generation of new blood vessels and tissue repair mechanisms.

"The occlusion of small blood vessels, similar to the occlusions which may develop in the pipes of an aging' home, is a dominant element in the human aging process. This led us to speculate that HBOT may affect brain performance of the aging population," Prof. Efrati explained. "We found that HBOT induced a significant increase in brain blood flow, which correlated with cognitive improvement, confirming our theory. One can conjecture that similar beneficial effect of HBOT can be induced in other organs of the aging body. These will be investigated in our upcoming research."

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

Read this article:
Hyperbaric Oxygen Therapy Boosts Cognitive Function in Older Adults, Says Study - Technology Networks

Life Science Reagent Market Global Analysis and Research Report 2020 to 2026 | High Throughput Genomics Inc., Illumina Inc., Abbott Laboratories -…

The Life Science Reagent Market 2020 report is a comprehensive, professional, and in-depth research of the market that delivers significant data for those who are seeking information for the Life Science Reagent industry. The market report delivers the specification, key strategies, future prospects, and cost structure of the industry. The report also highlighted the future trends in the Life Science Reagent market that will impact the demand during the forecast period.

Exclusive offer: Up to 30% discount on this report

Available Exclusive Sample Copy of this Report at:

https://www.marketinsightsreports.com/reports/07152146223/global-life-science-reagent-market-insights-and-forecast-to-2026/inquiry?source=jewishlifenews&Mode=DP

The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.Top Companies in the Global Life Science Reagent Market: High Throughput Genomics Inc., Illumina Inc., Abbott Laboratories, Abcam, Emd Millipore, Biolog, Cell Sciences, Lonza Group Ag, Cell Signaling Technology, Thermo Fisher Scientific Inc., Trilink Biotechnologies, Cepheid Inc., Olympus Corp., Biomyx Technology, Abgent Inc.

Global Life Science Reagent Market Split By Product Type And Applications:

This report segments on the basis of Types:

Cell Biology Reagents

Animal Models

Recombinant Proteins

Othes

Split On the basis of Applications:

Stem Cell Research

DNA Research

RNA Research

Protein Detection

Others

Research Methodology of Life Science Reagent Market Report:

The global Life Science Reagent market study covers the estimation size of the market both in terms of value (Mn/Bn USD) and volume (x units). Both top-down and bottom-up approaches have been used to calculate and authenticate the market size of the Life Science Reagent market, and predict the scenario of various sub-markets in the overall market. Primary and secondary research has been thoroughly performed to analyze the prominent players and their market share in the Life Science Reagent market. Further, all the numbers, segmentation, and shares have been gathered using authentic primary and secondary sources.

Inquiry For Discount:

https://www.marketinsightsreports.com/reports/07152146223/global-life-science-reagent-market-insights-and-forecast-to-2026/discount?source=jewishlifenews&Mode=Dp

Important Features That Are Under Offering And Key Highlights Of The Reports:

The purpose of this report is to present a comprehensive assessment of the market and contain thoughtful insights, facts, historical data, industry-validated market data, and projections with a corresponding set of assumptions and methodologies. This report also helps to understand the global dynamics of Life Science Reagent Market, the structure by identifying and analyzing market segments, and the global market size of the project. Furthermore, the report also focuses on the competitive analysis of the key players with the product, pricing, financial position, product portfolio, growth strategy, and regional presence. The report also provides a PEST analysis, these PORTER analysis, and SWOT analysis to answer questions from shareholders to prioritize efforts and investments for the segment immediately appear in the Global Life Science Reagent Market.

We Also Offer Customization on report based on specific client Requirement:

Free Country Level analysis for any5 countriesof your choice.

Free Competitive analysis of any5 keymarket players.

Free 40 analysthours to cover any other data point.

Note: All the reports that we list have been tracking the impact of COVID-19 on the market. Both upstream and downstream of the entire supply chain has been accounted for while doing this. Also, where possible, we will provide an additional COVID-19 update supplement/report to the report in Q3, please check for with the sales team.

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information, and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.

CONTACT US:

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

[emailprotected] | [emailprotected]

Original post:
Life Science Reagent Market Global Analysis and Research Report 2020 to 2026 | High Throughput Genomics Inc., Illumina Inc., Abbott Laboratories -...

Stem Cell Therapies Market to Witness a Pronounce Growth During 2015-2025 – Jewish Life News

With 1000+ market research reports and 1 billion+ data points, Future Market Insights (FMI) serves each and every requirement of the clients operating in the global healthcare, pharmaceuticals, and medical device industries. FMI deploys digital intelligence solutions to offercompelling insights to report buyersthat help them in overcoming market challenges, especially at the time of a crisis. Our dedicated team of professionals performs an extensive survey for gathering accurate information associated with the market.

FMI, in its upcoming business report, elaborates the historical and current scenario of the global Stem Cell Therapies market in terms of production, consumption, volume, and value. The report scrutinizes the market into various segments, regions and players on the basis of demand pattern and growth prospects.

Crucial information and forecast statistics covered in the Stem Cell Therapies market report will arm both existing and emerging market players with necessary insights to craft long-term strategies as well as maintain business continuity during a crisis such as the ongoing COVID-19 pandemic.

COVID-19 Impact Analysis on Stem Cell Therapies Market

The recent outbreak of the COVID-19 has turned the spotlight on the healthcare industry, and subsequently impacted the Stem Cell Therapies market. Severe shortages of critical medical supplies and a rapid rise in number of COVID-19 cases have resulted into a revolution rather than evolution in the healthcare ecosystems. Consequently, the impact is noticeable in the Stem Cell Therapies market.

Following governments measures, particularly social distancing norms and stay-at-home orders, doctors are delaying or postponing elective surgeries unless critical to prevent the spread of the virus to individuals with comorbidities or chronic conditions. Additionally, movement restrictions and supply chain disruptions have created a logistical nightmare for market players, leading to severe product shortages in the global marketplace.

The FMIs report includes an interesting chapter on preliminary impact of the COVID-19 on the Stem Cell Therapies market. This allows both leading and emerging market players to understand the market scenario during a crisis and aids them in making sound decisions to gain a distinct competitive edge.

To Get the Sample Copy of Report visit @

https://www.futuremarketinsights.com/reports/sample/rep-gb-1087

Why Choose Future Market Insights

Discounted prices for new customers! Offer expires soon!

Stem Cell Therapies Market: Segmentation

Valuable information covered in the FMIs Stem Cell Therapies market report has been segregated into key segments and sub-segments.

By Treatment

By Application

By end user

Download Methodology of this Report @

https://www.futuremarketinsights.com/askus/rep-gb-1087

Stem Cell Therapies Market: Competition Analysis

The FMIs study presents a comprehensive analysis of global, regional, and country-level players active in the Stem Cell Therapies market.Competitive information detailed in the Stem Cell Therapies market report has been based on innovative product launches, distribution channels, local networks, industrial penetration, production methods, and revenue generation of each market player. Furthermore, growth strategies and mergers & acquisitions (M&A) activities associated with the players are enclosed in the Stem Cell Therapies market report.

Key players covered in the report include:

Request for covid19 impact Analysis @

https://www.futuremarketinsights.com/covid19/rep-gb-1087

Important Questions Answered in the Stem Cell Therapies Market Report

Key Offerings of the Report

See the article here:
Stem Cell Therapies Market to Witness a Pronounce Growth During 2015-2025 - Jewish Life News

The Baxter Foundation supports USC research on epilepsy and lung injury – USC News

The Donald E. and Delia B. Baxter Foundation is supporting innovative biomedical research at the Keck School of Medicine of USC by granting $100,000 awards to two assistant professors: Vishal Patel, MD, PhD, in the USC Mark and Mary Stevens Neuroimaging and Informatics Institute (INI) and Ya-Wen Chen, PhD, in the USC Hastings Center for Pulmonary Research and the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC. In addition, the foundation has given $100,000 in support of the Medical Student Summer Research Fellowship program at the Keck School.

Patel will use his award to study regions of abnormal brain tissue that cause seizures in epilepsy patients using ultra-high field 7 Tesla magnetic resonance imaging (MRI). The INIs Siemens Magnetom Terra is the most powerful MRI scanner that is FDA-approved for clinical use, and one of only two such systems currently operating in the United States. This unique instrument will allow Patel to generate extremely highresolution, tailored images of patients brains to pinpoint irregularities.

We hope that this approach will allow us to identify abnormal brain tissue in more individuals compared to standard MRI, Patel said, and thus offer thepotential for a surgical cure to more of our patients who suffer fromdrug-resistant epilepsy.

Chen will use her $100,000 Baxter award to determine how stem cells repair lung injuries in human patients.

To study this process, Chen and her team will collect adult skin or blood cells, reprogram them into induced pluripotent stem cells, and direct them to generate a specific type of lung stem cell. The scientists will then direct these lung stem cells to develop into simplified lung structures known as organoids.

Were using lung organoids to take a close look at two key molecular signalscalled hypoxic and Wntthat determine whether lungs repair themselves well or badly, said Chen, who is an assistant professor of medicine, and stem cell biology and regenerative medicine. This could offer important clues about how we can avoid bad repair, such as fibrosis, in patients with serious lung injuries due to acute respiratory distress syndrome.

Since 1959, the Baxter Foundation has supported USCs early-career investigators and medical students as they perform research to develop new treatments for patients. USC is one of several California educational and scientific institutions that have benefitted from the foundations longstanding commitment to advancing research and medical innovations.

We are so pleased to be able to continue our support of USC with these new awards to Drs. Chen and Patel, and with the research fellowships for medical students, said Jane Haake Russell, president of the Baxter Foundation. By supporting these gifted researchers at the beginning of their careers, we are able to fulfill the foundations important mission of advancing medical research to develop new approaches for alleviating pain and prolonging human life.

View post:
The Baxter Foundation supports USC research on epilepsy and lung injury - USC News

A coagulation defect arising from heterozygous premature termination of tissue factor. – Physician’s Weekly

Tissue factor (TF) is the primary initiator of blood coagulation in vivo and the only blood coagulation factor for which a human genetic defect has not been described. As there are no routine clinical assays that capture the contribution of endogenous TF to coagulation initiation, the extent to which reduced TF activity contributes to unexplained bleeding is unknown. Using whole genome sequencing, we identified a heterozygous frameshift variant (p.Ser117HisfsTer10) in F3, the gene encoding TF, causing premature termination of TF (TFshort) in a woman with unexplained bleeding. Routine hematological laboratory evaluation of the proposita was normal. CRISPR-edited human induced pluripotent stem cells recapitulating the variant were differentiated into vascular smooth muscle and endothelial cells that demonstrated haploinsufficiency of TF. The variant F3 transcript is eliminated by nonsense-mediated decay. Neither overexpression nor addition of exogenous recombinant TFshort inhibited factor Xa or thrombin generation, excluding a dominant negative mechanism. F3+/- mice provide an animal model of TF haploinsufficiency and exhibited prolonged bleeding times, impaired thrombus formation, and reduced survival following major injury. Heterozygous TF deficiency is present in at least 1 in 25,000 individuals and could limit coagulation initiation in undiagnosed individuals with abnormal bleeding but a normal routine laboratory evaluation.

PubMed

Original post:
A coagulation defect arising from heterozygous premature termination of tissue factor. - Physician's Weekly

Adult Stem Cell Success Story Leukemia | BRMS

When doctors diagnosed Mary Lou Rusco with leukemia, Steve Rusco did what any other husband would do: he went looking for answers in hopes of saving the life of his wife. What he discovered scared him.

Youd like to think that medicine always has an answer, recalls Steve as he searched for treatments and cures to the blood disease that claims the life of nearly half of all leukemia patients. But I soon became aware there was not an answer. There was nothing that they could do to cure Mary Lous leukemia other than maybe put it into remission. Even if they did that, the leukemia showed that it could come back.

In fact, chemotherapy treatment did place Mary Lous leukemia into remission, but nine months later it was back. The prognosis moving forward was not encouraging.

Emotionally it was very difficult, said Mary Lou. I just thought, I have too much to live for. I have my grandkids and, you know, I love life.

The end, it seemed, was quickly approaching. Youre confronted with the reality, theres no way out, said Steve. Its just a matter of time. And that, in itself, is haunting.

At the darkest hour, despair turned to hope. The Ruscos got a phone call from doctors at the University of Kansas Medical Center.

They told me they thought they had something that might work for me, said Mary Lou. And it was the stem cell transplant, which they hadnt been doing on people over 55 and had only used on babies. And so I was one of the first few to get the umbilical cord (adult stem cell) transplant from KU.

The umbilical cord blood rich in adult stem cells came from two children, a girl from Texas and a boy from Missouri, whose mothers had donated the umbilical cord blood at birth. Once Mary Lous diseased immune system was wiped out by chemotherapy and radiation, the new adult stem cells harvested from the umbilical cord blood were injected into her bloodstream.

But would the transplant work? Time would tell. The post-transplant recovery was a physical and emotional roller coaster lasting nearly four months, requiring nearly round-the-clock care provided by Steve and by Charlotte Steffen, a friend and registered nurse from her church in Wichita, Kansas.

She was my angel, says Mary Lou of Charlottes efforts. Basically she gave up her summer just to be with me and take care of me. Ill be forever grateful.

Slowly but surely, Mary Lou began recovering her strength. She finally returned home to begin living her life again. Because the adult stem cells taken from umbilical cord blood are still maturing, Mary Lous immune system is still developing its shield of protection against diseases and infections. But there is no denying that the adult stem cell transplant saved her life. She spends time with her grandchildren and is in awe of whats happened.

Its a miracle, declares Mary Lou. I mean it truly is a miracle how they can take those little umbilical cord (adult) stem cells and cure leukemia. Because as far as Im concerned, Im cured. They havent said it yet, but I feel like Im cured. Its meant that much to me.

Adult stem cells give you a chance for life, adds Steve. You know, God bless the people that have taken the time to donate their (umbilical cord) stem cells so that others might have an opportunity at life. They gave us a gift and were going to live each day as a blessing.

Source: Stem Cell Research Facts

Excerpt from:
Adult Stem Cell Success Story Leukemia | BRMS

Investing in Life Sciences Stocks and Companies – Nanalyze

Nowhere will you find more exciting ideas to invest in than life sciences, a broad topic that encompasses around 30 different branches of study, each of which could take a lifetime to fully comprehend. As investors, we dont want to rely on subject matter experts to understand what a company does. If we cant understand a companys business, we dont want to invest in it. We also want to avoid businesses with no traction. Drug development companies with no revenues that are burning through cash trying to bring a drug to market have volatile share prices for a reason. That volatility represents uncertainty. We prefer to stick with businesses that are already selling a product or service which is generating strong revenue growth consistently. These are businesses that are leveraging life sciences technologies to achieve above-average growth.

In writing about life sciences over the past seven years, weve come across dozens of interesting life sciences companies innovating across the globe such as:

Oftentimes well find groups of startups trying to solve similar problems like creating treatments using the human microbiome or trying to cure hearing loss. Technologies like mobile health, telemedicine, and medical chatbots are democratizing access to healthcare services. Big data is helping us better treat mental health conditions while telepsychiatry now democratizes access to mental health professionals. Were now able to create bionic limbs, bionic eyes, bionic ears, bionic pancreases, and artificial hearts. Soon, we might be harvesting organs from pigs to help solve the kidney transplant problem. Robots are now performing surgeries, and it wont be long until robots are doing dental work as well. Were building labs in the cloud and organs on chips. Optogenetics lets us control cells in living tissues with light. Deep learning algorithms now discover drugs which are then administered using smart pills, smart inhalers, or even wireless drug delivery chips. Patient data is now stored using electronic medical records, data which can then be analyzed by artificial intelligence algorithms to provide things like personalized cancer treatments. When a baby is born, were able to store stem cells from cord blood and then use them for stem cell transplants later on in life. These are only the startups we know about, because many life sciences startups choose to operate in stealth mode.

Some of the problems were trying to solve are themselves emerging, such as trying to kill super bugs that stem from antibiotic resistance, or developing vaccines for new viruses like the rona. (Johnson & Johnson is pouring millions into developing a coronavirus vaccine.) Many of the problems being worked on involve cures that havent been developed yet, something we looked at in our when will there be a cure series.

Examples of innovation in life sciences abound, so weve tried to narrow it all down to six areas of focus weve been researching for investment opportunities.

Lets start with genomics.

Perhaps no field in life sciences shows more promise than that of genomics. Using genetic sequencing machines, scientists are not only able to read the recipes of life, theyre also able to edit them using technologies like gene editing. Full genome sequencing has now fallen below the $1,000 mark, and some companies now have their sites set on a $50 genome sequencing price point.

Huge databases of DNA data are now being mined for insights, and scientists are even able to reconstruct composite images of criminals form crime scenes using DNA, something referred to as DNA phenotyping.

The field of genomics is exploding as prices plummet, speeds increase, and companies continue to find new use cases. Venture capitalists are pouring money into genomics startups across the globe with China and America being seen as the current leaders in genomics. In the future, well have a world where everyone is given personalized medicine tailored to their unique genetic makeup. This is why genetic testing is becoming so popular, something well cover extensively later in this piece.

You cant talk about genomics without mentioning Illumina, a company that all but dominates the market for machines that perform gene sequencing. Weve been longtime shareholders in Illumina and added to our position back in 2016 when shares dipped to around $135 a share. As the cost of gene sequencing plummets, even more use cases are opening up for Illuminas machines leaving them plenty of room for growth. One company trying to disrupt this plan is Chinas BGI Genomics which hopes to provide an alternative for Chinese companies that dont want to use Illumina or Oxford Nanopore sequencing machines. (Oxford Nanopore is a private company that builds smaller gene sequencing devices that are less accurate.) Another publicly traded company to watch in the sequencing space is 10X Genomics which is working on single cell sequencing.

Not all genomics stocks are leaders. There are plenty of laggards, like Bionano Genomics (BNGO) which had an IPO back in 2018. The company sells instruments meant to complement next-generation sequencing machines like those sold by Illumina. Unfortunately, they couldnt grow revenues in 2019 while losses continued to increase. You cannot be in a high-growth market and not have the revenue growth to show for it.

Human longevity also referred to as life extension science involves extending the human lifespan by rolling back the effects of aging. Technologies like machine learning and genetic sequencing now mean were better able to understand the aging process. Companies like Googles Calico are analyzing millions of anonymous DNA samples in an attempt to better understand the effects of genetics on aging.Were now able to develop cellular medicines that uses live cells to repair the body.

Other companies are trying to increase the human lifespan by lengthening ones telomeres or by minimizing oxidization which causes aging. Venture capitalists are pouring money into dozens of startups tackling the aging problem in areas like regenerative medicine or young blood transfusions.

From an investors perspective, human longevity presents both risks and potential rewards as living another 20 years can have some dire effects on some peoples retirement plans. Of the top longevity companies out there, some are publicly traded. Just be aware that some companies out there are selling snake oil. Theyre preying on older people who have money and the desire to live longer. Just because someone says theyre selling anti-aging pills doesnt mean they actually work.

Weve talked before about how The Internet of Things promises to connect everything to the cloud with the byproduct being loads of big data. The same holds true in the medical industry where connected medical devices allow doctors to monitor patients vital signs from afar. Breath diagnostics devices allow us to more quickly diagnose medical conditions. Ultrasounds can now be performed with smartphones, and ultrasound technology itself is finding many other uses cases like breaking up blood clots that cause strokes. Newly developed medical devices are used to administer electroceutical therapies and wearables are helping to treat mental health.

Perhaps some of the biggest advancements are being made in medical imaging where deep learning algorithms are used to interpret medical imagery. Dozens of startups are now developing medical imaging AI algorithms to do everything from measuring breast density to preparing surgeons for surgery.

The increasing sophistication of medical devices and medical imaging algorithms mean that doctors are more easily able to treat patients from afar. Companies like Teladoc (TDOC) make it possible for anyone with $40 to speak with a doctor. For retail investors looking to invest in the telemedicine trend, Teladoc is probably the only telehealth stock to own. There are also many startups working on telehealth using technologies like machine learning to improve upon their offerings.

As we continue to develop more connected medical devices and generate more medical images, the amount of big data to analyze in healthcare is growing exponentially. Many data analytics businesses are emerging which use this data for predictive analytics or to identify inefficiencies in processes. The ability to remotely monitor patients means were able to treat more people, more effectively.

A good example of remote patient care can be found in iRhythm Technologies (IRTC). Theyve built their entire business around a medical device for remote cardiac monitoring. It comes in the form of a wearable that can capture up to two weeks of ECG data while allowing the patient to conduct their life in a perfectly normal fashion. All that data is then fed to a deep learning model capable of arrhythmia detection at a level comparable to a panel of expert cardiologists for a total of 12 output classes.

Most patient data is now stored electronically instead of being stuffed in some filing cabinet. This means a patients data can be shared across healthcare providers allowing for better care. For retail investors, there are a number of publicly traded companies working on electronic health records (EHRs) which are rapidly becoming the norm. Practice Fusion even offers EHRs for free because they know the value is in the data. Companies like Health Catalyst (HCAT) then apply healthcare data analytics to all this big data to create large-scale efficiencies.

A brain-computer interface might be the Holy Grail for human advancement. Just imagine being able to increase your brain storage capacity exponentially. And its not just about augmenting the human brain. Being able to interface with the human brain means we no longer need to use keyboards or mice. Dozens of startups are working on neurotech applications like neuroprosthetics which can rectify brain damage or neuromodulation which can be used for pain management.

Our brains contain about 2.5 petabytes (2,500,000 gigabytes) of storage, enough to store the entire contents of all US academic research libraries.Stentrodes and neural dust are just some of the methods being used to access this incredible biological data storage mechanism. Biohackers can even do this at home using technologies like OpenBCI.

If youre not familiar with the drug discovery process, its largely inefficient with billions of dollars being spent developing drugs that never actually get approved following clinical testing.

Plenty of companies are working on removing all the inefficiencies from the process. For example, a handful of startups are working on helping patients find clinical trials worldwide which they can then participate in from home. Some of the biggest advancements being made in drug discovery are the many computational drug discovery startups popping up which use machine learning to optimize the discovery process.

When drugs do get approved, some create more problems than they solve. Look no further than Americas addiction to opiates which helps explain the proliferation of startups developing substance abuse apps. Many mental health problems stem from drug abuse, so sometimes cognitive behavioral therapies are a better option than hard drugs. Some of the more severe mental health conditions like schizophrenia still arent being treated effectively which means theres still lots more work to be done.

There is no cure for cancer, theres only early detection which could make most cancers benign. Thats just one example where advancements in medical testing could prove to save lives and money, something that everyone working in medicine wants to do. Unfortunately there have been some setbacks for investors, the most notable being the implosion of Theranos. Elizabeth Crazy Eyes Holmes was behind the blood testing company which was fawned over by just about everyone. Now, shes facing criminal charges while other companies try to fill the Theranos void with their own platforms for blood testing. Some of these come in the form of mobile diagnostics platforms that can be used at the point of care.

Advances in medical testing run the gamut, from AI algorithms that detect Alzheimers to blood tests that detect cancer. Were now able to use next-generation sequencing technologies to identify genomic sequences of pathogens that are present in a patients blood or even circulating tumor cells that indicate cancer. Were even working on building the tricorder from Star Trek.

Many companies are now able to detect the presence of cancer in biofluids like blood or urine. It isnt just about early detection, its also about monitoring the progress of cancer treatments. Traditionally, a doctor would take a piece of a tumor a biopsy in order to determine if it is cancerous or benign. Now, many startups are developing liquid biopsies or blood tests that are capable of detecting cancer. One publicly traded in this space is Guardant Health (GH), an $8 billion precision oncology company that primarily sells cancer blood tests.

Once a type of cancer has been identified, we can then use next-generation sequencing to identify cancer-associated alterations thatcan be attacked usingtargeted therapies.Foundation Medicine is a leader in this space with one of the worlds largest cancer genomic databases, holding more than 400,000 genomic profiles. The company had an IPO back in 2013 and got into bed with Roche a few years later. They were finally acquired by Roche in 2018.

Across the pond we have a few publicly traded companies in this space as well. Angle (AGL:LN), a $95 million company which continues to bleed cash while generating minuscule revenues, offers liquid biopsies. Oxford Immunotec (OXFD) is having a bit better luck on the revenue side of things with their blood test for tuberculosis.

Apocell used to be publicly traded but has since been taken private. Theres also a Japanese firm called Sysmex (6869:JP) which is the global market leader inhematology,occupying the number-oneshare of theworldwide market. They have a subsidiary called Sysmex Inostics which has developed an ultra-sensitivedigital PCR technologythat is capable of detecting cancer cell DNA directly from blood.

Blood isnt the only bodily byproduct used to detect cancer. A $13 billion company called Exact Sciences (EXAS) sells a stool DNA test for colorectal cancer. Exosome Diagnostics acquired by Bio-Techne is developing a urine test for prostate cancer. All these samples flying around mean that entire businesses are now being built around the storage and transportation of biological samples.

There are also companies developing cancer therapies that are fine-tuned to certain genomic profiles like personalized chemotherapy. This is where some genetics testing comes in handy.

To say that genetic testing has exploded is an understatement. There are now genetic tests for nearly everything, including genetics tests for pets. In looking at some of these testing use cases, they seem to be borderline gimmicks like DNA dating or genetic fitness tests. Others provoke a great deal of controversy, like genetic tests for intelligence. There are now DNA apps for nearly everything, but where it all started was with ancestry genetic tests.

Large ancestry testing companies like 23andMe and Ancestry.com quickly realized that the real value to be had was not in selling genetic tests, but collecting genetic data and monetizing it. This quickly led to privacy concerns around genetic data. As more and more companies started offering genetic testing services, the big providers started to pivot into genetic healthcare tests for hereditary diseases like cancer or heart disease. Soon, this started to attract the attention of regulatory authorities. Telling someone their dad isnt their dad isnt nearly as painful as mistakenly getting a double mastectomy because a genetic test said you were at risk for breast cancer. Youd be surprised to see how many ancestral differences you get when you run the same DNA sample through multiple test providers. (This is why Family Tree DNA offers a central DNA results database where you can upload all your test results.) When it comes to health related genetics testing, accuracy is paramount.

The evolution of genetics testing is now leading to new business models that try to adapt to the environment. Nebula now offers anonymous DNA testing. Centogene is building the worlds largest repository for genetic information on rare hereditary diseases in the world. Were learning more about how polygenic risk scores can help predict disease. Being able to interpret genetic data is becoming much easier thanks to technologies like machine learning. Even with all these new technologies, theres still an important human element to the whole thing. Finding out that youre at risk for hereditary cancer isnt all that useful unless someone tells you exactly what that means and what steps you should take if any.

For retail investors, theres one pure-play genetic testing stock you ought to consider which just expanded into personalized oncology with their acquisition of ArcherDX Invitae (NVTA). Since we first came across the company seven years ago, theyve come a long way.

Some other themes weve looked at manifest themselves over time as we notice their prevalence. For example, who knew that diabetes would be such a big industry.

All these people who talk about how big is beautiful need to realize that its just not. Sure, there are some cultures that glorify obesity because it represents wealth and security. In America, fat asses abound because people drive up to windows to consume two days of calories in one seating which they then wash down with a diet soda.

The hard truth is that obesity is unhealthy and a contributing factor to a huge global problem diabetes. Weve talked before about why there isnt a cure for diabetes yet. Until there is, we need to treat the more than 100 million U.S. adults who are now living with diabetes or prediabetes.

All kinds of companies are working on diabetes treatments. Dance Biopharm (now Aerami Therapeutics) is working on an inhaled insulin product. Intarcia Therapeutics is working on a potential once-a-year diabetes treatment. But no matter how compelling these products sound, there will be failures, like Cellnovos attempt at developing insulin pumps. Kind of hard to compete with Medtronic (MDT), one of the worlds biggest medical device makers, which already has that sorted with a digital form of an artificial pancreas. (Full disclosure: were long-time shareholders in MDT for dividend growth reasons.)

Another theme we looked at for a bit was non invasive prenatal testing (NIPT) which is pretty much what it says on the tin. Its a test that makes sure your little bundle of joy doesnt pop out with two heads, or be afflicted by any malady that would interfere with the perfect life youve planned for it. Plenty of companies are dabbling in this space, like Ariosa Diagnostics which was acquired by Roche since we last looked at them. Other publicly traded stocks in this space include Natera (NTRA) and Premaitha Health (YGEN:LN) which now goes under the name Yourgene.

We stopped looking at NIPT because we believed the NIPT growth story might be ending. We also didnt find the topic to be that interesting frankly unless of course they come out with a NIPT for intelligence which wed probably invest in.

Stem cells are kind of like a foundation cell that various types of other cells get built on like muscle cells or brain cells. These are useful for applications like regenerating body parts or figuring out what makes cancer cells replicate. One company we looked at, Cellular Dynamics, was in the business of producing stem cells. Theyve since been acquired by Fujifilm Holdings. Another company we looked at was Fate Therapeutics (FATE) which uses renewable master induced pluripotent stem cell (iPSC) lines to produce cellular immunotherapies. We have no idea what that actually means, which is why were not investors in the company. We only like to invest in businesses we can easily understand.

Over the years of developing our life sciences topics, we encountered quite a few companies that we just didnt fully understand. Roivant Sciences was one of them. So were the nant companies coming from the brain of Dr. Soon Shiong, one of the worlds most successful biotech investors. Its very difficult to understand some of these businesses without having a medical background, and if you need eight years of training to understand what a company does, its probably too complex for retail investors. Weve given up on trying to figure out how Nanthealth will revolutionize the U.S. healthcare system, or what Nantkwest does, and instead stick to companies with business models anyone can understand. Another area of life sciences weve looked into before but decided not to follow is RNAi therapeutics.

Another area we looked at briefly was RNAi therapeutics and publicly-traded RNAi companies like Benitec, Dicerna Pharmaceuticals, or Moderna which has soared after going public due to their work on a coronavirus vaccine. To this day, we still dont feel like we sufficiently understand what many of these companies do which means were not able to properly explain them to our readers. Instead of spending hours trying to understand how microRNA relates to RNAi, were staying away from drug development companies entirely. Even if a company has the greatest drug development platform in the world, theres always a risk theyll fail given all the pitfalls of drug development we discussed earlier. The exception to that rule might be the drug development arm of Johnson & Johnson, a company we hold as part of our dividend growth investing strategy.

Fields like cancer immunotherapy, cancer stem cell research, or epigenetics may have loads of promise, but most of these investments are just too complex for your average Joe investor to understand without having an interpreter. Lets talk about some stocks that you dont need an interpreter to understand.

Given the breadth of technologies to be found under life sciences we often take fleeting looks at companies that are doing cool things without necessarily doing any deep-dives or follow ups. These one-offs are oftentimes stocks or planned IPOs we come across that we think our readers might find interesting.

One thing all these stocks have in common is that theyre traded on major exchanges unlike penny stocks which you should avoid like the plague.

We never skip a chance to warn investors about the dangers to be found when dabbling in penny stocks (also called over-the-counter (OTC) stocks). Here are just some of the OTC companies weve written about.

Investing in any these companies would have proved to be a total disaster. Of course there are always some exceptions, but why try to walk through landmines to find them? Do not speculate on penny stocks, no matter how compelling their story is.

Oftentimes well come across micro-cap stocks on foreign exchanges which well write about. More often than not, these companies will end up going nowhere fast. Kiwi company Adherium (ADR:AU) was supposed to bring us intelligent inhalers. While investors continue to wait, their share price continues to plummet. We warned investors that Canadian firm BioMark Diagnostics (BUX:CN) might not have what it takes to bring cancer blood tests to market, and the company still appears to be going nowhere fast. Londons Tissue Regenix (TRX:LN) was working on some exciting new skin scaffolds, but you would have lost -90% of your investment waiting for them to finally start achieving some traction. Even though revenues are picking up and losses are trending in the right direction, shares continue their long downward slide. Its best not to try and catch a falling knife.

Some readers may wonder why we havent touched on one of the most exciting technology there is synthetic biology. Thats because weve dedicated an entire page to synthetic biology, our Guide to Investing in Synthetic Biology. The same holds true for gene editing, something we covered in our Guide to Investing in Gene Editing Stocks. We happen to classify gene editing and synthetic biology under our nanotechnology category, so you may want to go read our Guide to Investing in Nanotechnology Stocks and Companies next. Because life sciences is such a broad category, youll find it peppered throughout all the twelve categories of disruptive technologies we cover here at Nanalyze. For example, machine learning algorithms are now helping us understand extremely complex things such as the human microbiome.

Sure, you can cure your STDs without going to a doctor, but developing something as simple as a universal flu vaccine is still out of reach. While plenty of progress is being made in life sciences, there are still plenty of diseases we cant cure and problems we cant solve. Its safe to say that investors will continue to reap rewards by investing in life sciences companies for decades to come.

Interested in hearing more about investing in life sciences companies and stocks?Sign up for our weekly newsletter. Well keep you up-to-date on life sciences investments and all the disruptive technologies out there that ought to be on investors radar. No politics, no B.S., no corporate buzzword bingo.Click here to sign up for Nanalyze Weekly.

Follow this link:
Investing in Life Sciences Stocks and Companies - Nanalyze